Drug Profile
Antibody therapeutic - Merck
Latest Information Update: 16 Apr 2018
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 16 Apr 2018 Discontinued - Phase-I for Autoimmune disorders in USA (Parenteral)
- 28 Apr 2016 Phase-I development is ongoing in USA
- 10 Apr 2014 Phase-I clinical trials in Autoimmune disorders in USA (Parenteral)